Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

58392

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sunbeds
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the Government plans to respond to the recommendations set out in the report of the All Party Parliamentary Group on Skin on sunbed regulation published in 2014.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199381
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The Government has noted the report and is currently considering how to respond to the recommendations<strong>.</strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2014 15:23:48 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

58393

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the potential cost of extending the human papilloma virus vaccination programme to include all boys aged 12 and 13 years.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199382
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>We have not made any estimate of extending the human papillomavirus (HPV) vaccination programme to include boys aged 12 and 13 years, as the Joint Committee on Vaccination and Immunisation has not yet completed its consideration of whether HPV vaccine should be offered to males.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2014 14:44:56 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

58394

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Alcoholic Drinks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the Government's assessment is of the effectiveness of warning labels on alcoholic beverages regarding drinking during pregnancy; and what assessment he has made of the potential benefits of making such labels mandatory.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199389
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>Research in the evidence around the effectiveness of alcohol harm reduction communications and related campaigns suggests that labelling and point of sale information can have an impact on consumption, in conjunction with broader campaigns to raise consumer awareness and education on the health risks linked to alcohol consumption.</p><p><strong> </strong></p><p>As part of the Public Health Responsibility Deal, alcohol retailers and producers have committed to putting an agreed warning or a pregnancy warning logo on 80% of labels on bottles and cans by the end of 2013. An independent market survey is underway to measure compliance. This level of coverage should allow the majority of consumers to see the pregnancy warning and logo.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2014 15:29:37 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

58395

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Academic Health Science Networks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the running costs for each of the academic health science networks are.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199345
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The information requested is not available.</p><p> </p><p>NHS England advises us that individual funding levels and programme costs vary between Academic Health Science Networks (AHSNs). NHS England budget allocations are not their sole source of income and AHSNs are seeking to supplement this funding through participation in strategic investment programmes and match-funding initiatives. Core running costs are for AHSNs to determine independently and may also be subject to change through the year.</p><p> </p><p>Further information on AHSN work programmes and business plans can be found on their websites:</p><p> </p><table><tbody><tr><td><p>AHSN</p></td><td><p>Website</p></td></tr><tr><td><p>East Midlands</p></td><td><p><a href="http://www.emahsn.ac.uk/" target="_blank">www.emahsn.ac.uk</a></p></td></tr><tr><td><p>Eastern</p></td><td><p><a href="http://www.eahsn.org.uk/" target="_blank">www.eahsn.org.uk</a></p></td></tr><tr><td><p>Imperial College Health Partners</p></td><td><p><a href="http://www.imperialcollegehealthpartners.com/" target="_blank">www.imperialcollegehealthpartners.com</a></p></td></tr><tr><td><p>Greater Manchester</p></td><td><p><a href="http://www.gmahsn.org/" target="_blank">www.gmahsn.org</a></p></td></tr><tr><td><p>Kent, Surrey and Sussex</p></td><td><p><a href="http://www.kssahsn.net/" target="_blank">www.kssahsn.net</a></p></td></tr><tr><td><p>North East and North Cumbria</p></td><td><p><a href="http://www.ahsn-nenc.org.uk/" target="_blank">www.ahsn-nenc.org.uk</a></p></td></tr><tr><td><p>North West Coast</p></td><td><p><a href="http://www.nwcahsn.nhs.uk/" target="_blank">www.nwcahsn.nhs.uk</a></p></td></tr><tr><td><p>Oxford</p></td><td><p><a href="http://www.oxfordahsn.org/" target="_blank">www.oxfordahsn.org</a></p></td></tr><tr><td><p>South London</p></td><td><p><a href="http://www.kingshealthpartners.org/info/southlondonahsn" target="_blank">www.kingshealthpartners.org/info/southlondonahsn</a></p></td></tr><tr><td><p>South West Peninsula</p></td><td><p><a href="http://www.swahsn.com/" target="_blank">www.swahsn.com</a></p></td></tr><tr><td><p>UCL Partners</p></td><td><p><a href="http://www.uclpartners.com/" target="_blank">www.uclpartners.com</a></p></td></tr><tr><td><p>Wessex</p></td><td><p><a href="http://www.wessexahsn.org/" target="_blank">www.wessexahsn.org</a></p></td></tr><tr><td><p>West Midlands</p></td><td><p><a href="http://www.wmahsn.org/" target="_blank">www.wmahsn.org</a></p></td></tr><tr><td><p>West of England</p></td><td><p><a href="http://www.weahsn.net/" target="_blank">www.weahsn.net</a></p></td></tr><tr><td><p>Yorkshire and Humber</p></td><td><p><a href="http://www.yhahsn.org.uk/" target="_blank">www.yhahsn.org.uk</a></p></td></tr></tbody></table><p> </p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 10/06/2014 14:27:05 answering member 1439 label Biography information for Norman Lamb
tabling member	4036 label Biography information for Luciana Berger

58513

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199302
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199303 199304 question first answered 10/06/2014 15:28:08 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58515

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199303
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199304 question first answered 10/06/2014 15:28:10 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58516

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199304
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199303 question first answered 10/06/2014 15:28:11 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

57541

registered interest
date	04/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Records: Data Protection
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what are the rules relating to the release of patients' private medical information to insurance companies by general practitioners.
tabling member printed	Lord Trefgarne
uin	HL14
answer	answer is ministerial correction date of answer 11/06/2014 answer text <p>General practitioners (GPs) must ensure that patients have provided explicit consent before disclosing information to insurance companies. Additionally, under the provisions of the Access to Medical Reports Act 1988, patients have the right to view medical reports prepared for insurance companies and, where a patient has exercised this right, a GP cannot disclose the report to the insurance company until the patient has had the opportunity to review it or if the patient withdraws their consent.</p> answering member printed Earl Howe question first answered 11/06/2014 11:45:03 answering member 2000 label Biography information for Earl Howe
tabling member	1813 label Biography information for Lord Trefgarne

57554

registered interest
date	04/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mid Staffordshire NHS Foundation Trust
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what is their estimate of the cost of the special administration process in relation to Mid-Staffordshire NHS Trust.
tabling member printed	Lord Hunt of Kings Heath
uin	HL27
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The appointment of Trust Special Administrators (TSAs) to Mid-Staffordshire NHS Foundation Trust in April 2013 was made by Monitor. The TSAs' final proposals were accepted by Monitor in January 2014, and by the Secretary of State in February 2014.</p><p> </p><p>In an announcement on 13 March 2014, Monitor stated that the costs of the process to date had been £7,250,000, with an additional £250,000 incurred by the team of administrators in expenses.</p><p><strong> </strong></p><p>Following the Secretary of State's acceptance of the proposals, the TSAs have remained in post to continue with the day to day management of the Trust and to work on implementing the proposals.</p><p><strong> </strong></p><p>In the announcement Monitor anticipated that the overall cost of the TSA contract for the lifetime of the project would be between £12 million and £15 million.</p><p><strong> </strong></p><p>Monitor's announcement can be found on its website at:</p><p> </p><p>www.gov.uk/government/news/mid-staffs-monitor-announces-next-steps</p><p> </p> answering member printed Earl Howe question first answered 10/06/2014 15:28:17 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

57602

registered interest
date	04/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps are taken to verify the competence of (a) doctors and nurses and (b) staff of pharmaceutical companies involved in the conduct of clinical trials.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	198571
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) expect everyone involved in a clinical trial to be qualified and trained to perform their tasks (as per Schedule 1, part 2 (2) of the Medicines for Human Use (Clinical Trials) Regulations(SI 2004/1031).</p><p> </p><p>Staff of pharmaceutical companies are not “conducting” a trial as defined in the clinical trial regulation (SI 2004/1031 Reg 2 “interpretation”). However, the same Good Clinical Practice principles apply to those involved in clinical trial activities; i.e. they should be qualified and trained to perform their tasks. At sponsor site inspection, inspectors will verify the training records, CV, and job description of selected employees to confirm adequate training has been given.</p><p> </p><p>Sponsors are expected to carry out checks in audits or monitoring to ensure that on completion of training, staff are indeed carrying out their duties according to requirements and/or procedures (these checks should be documented in monitoring/audit reports). Inspectors check the monitoring visit reports to determine non-compliances are adequately followed up and re-training is given to site personnel when necessary.</p><p> </p><p>The voluntary MHRA Phase 1 Accreditation Scheme requires that a Principal Investigator (PI) for a First in Human study has relevant experience and a post graduate qualification in pharmaceutical medicine (such as a Diploma in Pharmaceutical medicine, Diploma in Human Pharmacology, MSc in Clinical Pharmacology or equivalent). An exemption to this requirement has been issued for PI's that do not have a post graduate qualification but are able to demonstrate that they have a significant amount of experience in this field (and are often involved in teaching the post-graduate courses). An application for an exemption is assessed independently by the Faculty of Medicine.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 10/06/2014 15:11:34 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1506 label Biography information for Andrew Gwynne